Treatment of postmenopausal osteoporosis with odanacatib

Bibliography

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-21
   PubMed Web of Science ®Google Scholar
• Chapurlat R. Contributions and limitations of the FRAX tool. Joint Bone Spine 2013;80:355-7
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with antiosteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004;15:120-4
   PubMed Web of Science ®Google Scholar
• Bessette L, SteMarie LG, Jean S, et al. The acre gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008;19:79-86
   PubMed Web of Science ®Google Scholar
• Marsh D, Akesson K, Beaton DE, et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 2011;22:2051-65
   PubMedGoogle Scholar
• Dawson-Hugues B, Tosteson ANA, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449-58
   Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408
   PubMed Web of Science ®Google Scholar
• Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012;79:304-13
   PubMed Web of Science ®Google Scholar
• Chavassieux P, Asser Karsdal M, Segovia-Silvestre T, et al. Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 2008;23:1076-83
   PubMedGoogle Scholar
• Barrett DG, Boncek VM, Catalano JG, et al. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2005;15:3540-6
   PubMed Web of Science ®Google Scholar
• Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 2007;40:122-31
   PubMed Web of Science ®Google Scholar
• Fuller K, Lindstrom E, Edlund M, et al. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K. Bone 2010;46:1400-7
   Google Scholar
• Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18:923-8
   PubMed Web of Science ®Google Scholar
• Kassahun K, Black CW, Nicoll-Griffith D, et al. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin K inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. Drug Metab Dispos 2011;39:1079-87
   PubMed Web of Science ®Google Scholar
• Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009;86:175-82
   PubMed Web of Science ®Google Scholar
• Li CY, Jepsen KJ, Majeska RJ, et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 2006;21:865-75
   PubMed Web of Science ®Google Scholar
• Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (−/−) mice. Bone 2009;44:199-207
   PubMed Web of Science ®Google Scholar
• Everts V, Aronson DC, Beertsen W. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 1985;37:25-31
   PubMed Web of Science ®Google Scholar
• Leung P, Pickarski M, Zhuo Y, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011;49:623-35
   Google Scholar
• Pennypacker B, Le Duong T, Cusick T, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2011;26:252-62
   PubMed Web of Science ®Google Scholar
• Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012;27:524-37
   PubMed Web of Science ®Google Scholar
• Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012;27:509-23
   PubMed Web of Science ®Google Scholar
• Williams DS, McCracken PJ, Purcell M, et al. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 2013;56(2):489-96
   PubMed Web of Science ®Google Scholar
• Cabal A, Jayakar RY, Sardesai S, et al. High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone 2013;56(2):497-505. Available from: http://dx.doi.org/10.1016/j.bone.2013.06.011
   Google Scholar
• Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25:937-47
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26(2):242-51
   PubMed Web of Science ®Google Scholar
• Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res 2013;27:2251-8
   Google Scholar
• Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013;98:571-80
   PubMed Web of Science ®Google Scholar
• Cheung AM, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry and estimated bone strength. J Bone Miner Res; In press
   Google Scholar
• Bonnick S, De Villiers T, Odio A, et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate – a randomized placebo-controlled trial. J Clin Endocrinol Metab 2013;98:4727-35
   PubMed Web of Science ®Google Scholar
• Update on phase III trial for odanacatib, Merck's investigational Cat-K inhibitor for osteoporosis. Available from: http://www.businesswire.com/news/home/20120711006535/en/Update-Phase-III-Trial-Odanacatib-Mercks-Investigational#.UrvdZFiA3cs
   Google Scholar